Global Late-Stage Oncology Drug Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
A late-stage oncology drug refers to a medication or treatment that has advanced through the initial phases of clinical trials (phases I and II) and is now being tested in phase III clinical trials or is awaiting regulatory approval for marketing. These drugs are typically intended for the treatment of cancer in patients who have advanced disease or have not responded well to standard treatments. Late-stage oncology drugs undergo rigorous testing to assess their safety, efficacy, and potential side effects in larger groups of patients before they can be approved for use in clinical practice.
The global Late-Stage Oncology Drug market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Late-Stage Oncology Drug Industry Forecast” looks at past sales and reviews total world Late-Stage Oncology Drug sales in 2023, providing a comprehensive analysis by region and market sector of projected Late-Stage Oncology Drug sales for 2024 through 2030. With Late-Stage Oncology Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Late-Stage Oncology Drug industry.
This Insight Report provides a comprehensive analysis of the global Late-Stage Oncology Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Late-Stage Oncology Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Late-Stage Oncology Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Late-Stage Oncology Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Late-Stage Oncology Drug.
United States market for Late-Stage Oncology Drug is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Late-Stage Oncology Drug is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Late-Stage Oncology Drug is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Late-Stage Oncology Drug players cover Roche, Merck & Co, Bristol Myers, Pfizer, Novartis, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Late-Stage Oncology Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Late-Stage Oncology Drug market?
What factors are driving Late-Stage Oncology Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Late-Stage Oncology Drug market opportunities vary by end market size?
How does Late-Stage Oncology Drug break out by Type, by Application?
A late-stage oncology drug refers to a medication or treatment that has advanced through the initial phases of clinical trials (phases I and II) and is now being tested in phase III clinical trials or is awaiting regulatory approval for marketing. These drugs are typically intended for the treatment of cancer in patients who have advanced disease or have not responded well to standard treatments. Late-stage oncology drugs undergo rigorous testing to assess their safety, efficacy, and potential side effects in larger groups of patients before they can be approved for use in clinical practice.
The global Late-Stage Oncology Drug market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Late-Stage Oncology Drug Industry Forecast” looks at past sales and reviews total world Late-Stage Oncology Drug sales in 2023, providing a comprehensive analysis by region and market sector of projected Late-Stage Oncology Drug sales for 2024 through 2030. With Late-Stage Oncology Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Late-Stage Oncology Drug industry.
This Insight Report provides a comprehensive analysis of the global Late-Stage Oncology Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Late-Stage Oncology Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Late-Stage Oncology Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Late-Stage Oncology Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Late-Stage Oncology Drug.
United States market for Late-Stage Oncology Drug is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Late-Stage Oncology Drug is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Late-Stage Oncology Drug is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Late-Stage Oncology Drug players cover Roche, Merck & Co, Bristol Myers, Pfizer, Novartis, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Late-Stage Oncology Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Hormonal Therapy
- Others
- Blood Cancer
- Breast Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Respiratory or Lung Cancer
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Roche
- Merck & Co
- Bristol Myers
- Pfizer
- Novartis
- AstraZeneca
- Johnson & Johnson
- Eli Lilly and Company
- Sanofi
- AbbVie
- GSK
- Amgen
- Genentech
- Daiichi Sankyo Group
- Aveo Oncology
What is the 10-year outlook for the global Late-Stage Oncology Drug market?
What factors are driving Late-Stage Oncology Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Late-Stage Oncology Drug market opportunities vary by end market size?
How does Late-Stage Oncology Drug break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Late-Stage Oncology Drug Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Late-Stage Oncology Drug by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Late-Stage Oncology Drug by Country/Region, 2019, 2023 & 2030
2.2 Late-Stage Oncology Drug Segment by Type
2.2.1 Chemotherapy
2.2.2 Targeted Therapy
2.2.3 Immunotherapy
2.2.4 Hormonal Therapy
2.2.5 Others
2.3 Late-Stage Oncology Drug Sales by Type
2.3.1 Global Late-Stage Oncology Drug Sales Market Share by Type (2019-2024)
2.3.2 Global Late-Stage Oncology Drug Revenue and Market Share by Type (2019-2024)
2.3.3 Global Late-Stage Oncology Drug Sale Price by Type (2019-2024)
2.4 Late-Stage Oncology Drug Segment by Application
2.4.1 Blood Cancer
2.4.2 Breast Cancer
2.4.3 Gastrointestinal Cancer
2.4.4 Prostate Cancer
2.4.5 Respiratory or Lung Cancer
2.4.6 Other
2.5 Late-Stage Oncology Drug Sales by Application
2.5.1 Global Late-Stage Oncology Drug Sale Market Share by Application (2019-2024)
2.5.2 Global Late-Stage Oncology Drug Revenue and Market Share by Application (2019-2024)
2.5.3 Global Late-Stage Oncology Drug Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global Late-Stage Oncology Drug Breakdown Data by Company
3.1.1 Global Late-Stage Oncology Drug Annual Sales by Company (2019-2024)
3.1.2 Global Late-Stage Oncology Drug Sales Market Share by Company (2019-2024)
3.2 Global Late-Stage Oncology Drug Annual Revenue by Company (2019-2024)
3.2.1 Global Late-Stage Oncology Drug Revenue by Company (2019-2024)
3.2.2 Global Late-Stage Oncology Drug Revenue Market Share by Company (2019-2024)
3.3 Global Late-Stage Oncology Drug Sale Price by Company
3.4 Key Manufacturers Late-Stage Oncology Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Late-Stage Oncology Drug Product Location Distribution
3.4.2 Players Late-Stage Oncology Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR LATE-STAGE ONCOLOGY DRUG BY GEOGRAPHIC REGION
4.1 World Historic Late-Stage Oncology Drug Market Size by Geographic Region (2019-2024)
4.1.1 Global Late-Stage Oncology Drug Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Late-Stage Oncology Drug Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Late-Stage Oncology Drug Market Size by Country/Region (2019-2024)
4.2.1 Global Late-Stage Oncology Drug Annual Sales by Country/Region (2019-2024)
4.2.2 Global Late-Stage Oncology Drug Annual Revenue by Country/Region (2019-2024)
4.3 Americas Late-Stage Oncology Drug Sales Growth
4.4 APAC Late-Stage Oncology Drug Sales Growth
4.5 Europe Late-Stage Oncology Drug Sales Growth
4.6 Middle East & Africa Late-Stage Oncology Drug Sales Growth
5 AMERICAS
5.1 Americas Late-Stage Oncology Drug Sales by Country
5.1.1 Americas Late-Stage Oncology Drug Sales by Country (2019-2024)
5.1.2 Americas Late-Stage Oncology Drug Revenue by Country (2019-2024)
5.2 Americas Late-Stage Oncology Drug Sales by Type (2019-2024)
5.3 Americas Late-Stage Oncology Drug Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Late-Stage Oncology Drug Sales by Region
6.1.1 APAC Late-Stage Oncology Drug Sales by Region (2019-2024)
6.1.2 APAC Late-Stage Oncology Drug Revenue by Region (2019-2024)
6.2 APAC Late-Stage Oncology Drug Sales by Type (2019-2024)
6.3 APAC Late-Stage Oncology Drug Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Late-Stage Oncology Drug by Country
7.1.1 Europe Late-Stage Oncology Drug Sales by Country (2019-2024)
7.1.2 Europe Late-Stage Oncology Drug Revenue by Country (2019-2024)
7.2 Europe Late-Stage Oncology Drug Sales by Type (2019-2024)
7.3 Europe Late-Stage Oncology Drug Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Late-Stage Oncology Drug by Country
8.1.1 Middle East & Africa Late-Stage Oncology Drug Sales by Country (2019-2024)
8.1.2 Middle East & Africa Late-Stage Oncology Drug Revenue by Country (2019-2024)
8.2 Middle East & Africa Late-Stage Oncology Drug Sales by Type (2019-2024)
8.3 Middle East & Africa Late-Stage Oncology Drug Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Late-Stage Oncology Drug
10.3 Manufacturing Process Analysis of Late-Stage Oncology Drug
10.4 Industry Chain Structure of Late-Stage Oncology Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Late-Stage Oncology Drug Distributors
11.3 Late-Stage Oncology Drug Customer
12 WORLD FORECAST REVIEW FOR LATE-STAGE ONCOLOGY DRUG BY GEOGRAPHIC REGION
12.1 Global Late-Stage Oncology Drug Market Size Forecast by Region
12.1.1 Global Late-Stage Oncology Drug Forecast by Region (2025-2030)
12.1.2 Global Late-Stage Oncology Drug Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Late-Stage Oncology Drug Forecast by Type (2025-2030)
12.7 Global Late-Stage Oncology Drug Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Roche
13.1.1 Roche Company Information
13.1.2 Roche Late-Stage Oncology Drug Product Portfolios and Specifications
13.1.3 Roche Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Roche Main Business Overview
13.1.5 Roche Latest Developments
13.2 Merck & Co
13.2.1 Merck & Co Company Information
13.2.2 Merck & Co Late-Stage Oncology Drug Product Portfolios and Specifications
13.2.3 Merck & Co Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Merck & Co Main Business Overview
13.2.5 Merck & Co Latest Developments
13.3 Bristol Myers
13.3.1 Bristol Myers Company Information
13.3.2 Bristol Myers Late-Stage Oncology Drug Product Portfolios and Specifications
13.3.3 Bristol Myers Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Bristol Myers Main Business Overview
13.3.5 Bristol Myers Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer Late-Stage Oncology Drug Product Portfolios and Specifications
13.4.3 Pfizer Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 Novartis
13.5.1 Novartis Company Information
13.5.2 Novartis Late-Stage Oncology Drug Product Portfolios and Specifications
13.5.3 Novartis Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Novartis Main Business Overview
13.5.5 Novartis Latest Developments
13.6 AstraZeneca
13.6.1 AstraZeneca Company Information
13.6.2 AstraZeneca Late-Stage Oncology Drug Product Portfolios and Specifications
13.6.3 AstraZeneca Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 AstraZeneca Main Business Overview
13.6.5 AstraZeneca Latest Developments
13.7 Johnson & Johnson
13.7.1 Johnson & Johnson Company Information
13.7.2 Johnson & Johnson Late-Stage Oncology Drug Product Portfolios and Specifications
13.7.3 Johnson & Johnson Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Johnson & Johnson Main Business Overview
13.7.5 Johnson & Johnson Latest Developments
13.8 Eli Lilly and Company
13.8.1 Eli Lilly and Company Company Information
13.8.2 Eli Lilly and Company Late-Stage Oncology Drug Product Portfolios and Specifications
13.8.3 Eli Lilly and Company Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Eli Lilly and Company Main Business Overview
13.8.5 Eli Lilly and Company Latest Developments
13.9 Sanofi
13.9.1 Sanofi Company Information
13.9.2 Sanofi Late-Stage Oncology Drug Product Portfolios and Specifications
13.9.3 Sanofi Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Sanofi Main Business Overview
13.9.5 Sanofi Latest Developments
13.10 AbbVie
13.10.1 AbbVie Company Information
13.10.2 AbbVie Late-Stage Oncology Drug Product Portfolios and Specifications
13.10.3 AbbVie Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 AbbVie Main Business Overview
13.10.5 AbbVie Latest Developments
13.11 GSK
13.11.1 GSK Company Information
13.11.2 GSK Late-Stage Oncology Drug Product Portfolios and Specifications
13.11.3 GSK Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 GSK Main Business Overview
13.11.5 GSK Latest Developments
13.12 Amgen
13.12.1 Amgen Company Information
13.12.2 Amgen Late-Stage Oncology Drug Product Portfolios and Specifications
13.12.3 Amgen Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Amgen Main Business Overview
13.12.5 Amgen Latest Developments
13.13 Genentech
13.13.1 Genentech Company Information
13.13.2 Genentech Late-Stage Oncology Drug Product Portfolios and Specifications
13.13.3 Genentech Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Genentech Main Business Overview
13.13.5 Genentech Latest Developments
13.14 Daiichi Sankyo Group
13.14.1 Daiichi Sankyo Group Company Information
13.14.2 Daiichi Sankyo Group Late-Stage Oncology Drug Product Portfolios and Specifications
13.14.3 Daiichi Sankyo Group Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Daiichi Sankyo Group Main Business Overview
13.14.5 Daiichi Sankyo Group Latest Developments
13.15 Aveo Oncology
13.15.1 Aveo Oncology Company Information
13.15.2 Aveo Oncology Late-Stage Oncology Drug Product Portfolios and Specifications
13.15.3 Aveo Oncology Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 Aveo Oncology Main Business Overview
13.15.5 Aveo Oncology Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Late-Stage Oncology Drug Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Late-Stage Oncology Drug by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Late-Stage Oncology Drug by Country/Region, 2019, 2023 & 2030
2.2 Late-Stage Oncology Drug Segment by Type
2.2.1 Chemotherapy
2.2.2 Targeted Therapy
2.2.3 Immunotherapy
2.2.4 Hormonal Therapy
2.2.5 Others
2.3 Late-Stage Oncology Drug Sales by Type
2.3.1 Global Late-Stage Oncology Drug Sales Market Share by Type (2019-2024)
2.3.2 Global Late-Stage Oncology Drug Revenue and Market Share by Type (2019-2024)
2.3.3 Global Late-Stage Oncology Drug Sale Price by Type (2019-2024)
2.4 Late-Stage Oncology Drug Segment by Application
2.4.1 Blood Cancer
2.4.2 Breast Cancer
2.4.3 Gastrointestinal Cancer
2.4.4 Prostate Cancer
2.4.5 Respiratory or Lung Cancer
2.4.6 Other
2.5 Late-Stage Oncology Drug Sales by Application
2.5.1 Global Late-Stage Oncology Drug Sale Market Share by Application (2019-2024)
2.5.2 Global Late-Stage Oncology Drug Revenue and Market Share by Application (2019-2024)
2.5.3 Global Late-Stage Oncology Drug Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global Late-Stage Oncology Drug Breakdown Data by Company
3.1.1 Global Late-Stage Oncology Drug Annual Sales by Company (2019-2024)
3.1.2 Global Late-Stage Oncology Drug Sales Market Share by Company (2019-2024)
3.2 Global Late-Stage Oncology Drug Annual Revenue by Company (2019-2024)
3.2.1 Global Late-Stage Oncology Drug Revenue by Company (2019-2024)
3.2.2 Global Late-Stage Oncology Drug Revenue Market Share by Company (2019-2024)
3.3 Global Late-Stage Oncology Drug Sale Price by Company
3.4 Key Manufacturers Late-Stage Oncology Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Late-Stage Oncology Drug Product Location Distribution
3.4.2 Players Late-Stage Oncology Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR LATE-STAGE ONCOLOGY DRUG BY GEOGRAPHIC REGION
4.1 World Historic Late-Stage Oncology Drug Market Size by Geographic Region (2019-2024)
4.1.1 Global Late-Stage Oncology Drug Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Late-Stage Oncology Drug Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Late-Stage Oncology Drug Market Size by Country/Region (2019-2024)
4.2.1 Global Late-Stage Oncology Drug Annual Sales by Country/Region (2019-2024)
4.2.2 Global Late-Stage Oncology Drug Annual Revenue by Country/Region (2019-2024)
4.3 Americas Late-Stage Oncology Drug Sales Growth
4.4 APAC Late-Stage Oncology Drug Sales Growth
4.5 Europe Late-Stage Oncology Drug Sales Growth
4.6 Middle East & Africa Late-Stage Oncology Drug Sales Growth
5 AMERICAS
5.1 Americas Late-Stage Oncology Drug Sales by Country
5.1.1 Americas Late-Stage Oncology Drug Sales by Country (2019-2024)
5.1.2 Americas Late-Stage Oncology Drug Revenue by Country (2019-2024)
5.2 Americas Late-Stage Oncology Drug Sales by Type (2019-2024)
5.3 Americas Late-Stage Oncology Drug Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Late-Stage Oncology Drug Sales by Region
6.1.1 APAC Late-Stage Oncology Drug Sales by Region (2019-2024)
6.1.2 APAC Late-Stage Oncology Drug Revenue by Region (2019-2024)
6.2 APAC Late-Stage Oncology Drug Sales by Type (2019-2024)
6.3 APAC Late-Stage Oncology Drug Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Late-Stage Oncology Drug by Country
7.1.1 Europe Late-Stage Oncology Drug Sales by Country (2019-2024)
7.1.2 Europe Late-Stage Oncology Drug Revenue by Country (2019-2024)
7.2 Europe Late-Stage Oncology Drug Sales by Type (2019-2024)
7.3 Europe Late-Stage Oncology Drug Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Late-Stage Oncology Drug by Country
8.1.1 Middle East & Africa Late-Stage Oncology Drug Sales by Country (2019-2024)
8.1.2 Middle East & Africa Late-Stage Oncology Drug Revenue by Country (2019-2024)
8.2 Middle East & Africa Late-Stage Oncology Drug Sales by Type (2019-2024)
8.3 Middle East & Africa Late-Stage Oncology Drug Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Late-Stage Oncology Drug
10.3 Manufacturing Process Analysis of Late-Stage Oncology Drug
10.4 Industry Chain Structure of Late-Stage Oncology Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Late-Stage Oncology Drug Distributors
11.3 Late-Stage Oncology Drug Customer
12 WORLD FORECAST REVIEW FOR LATE-STAGE ONCOLOGY DRUG BY GEOGRAPHIC REGION
12.1 Global Late-Stage Oncology Drug Market Size Forecast by Region
12.1.1 Global Late-Stage Oncology Drug Forecast by Region (2025-2030)
12.1.2 Global Late-Stage Oncology Drug Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Late-Stage Oncology Drug Forecast by Type (2025-2030)
12.7 Global Late-Stage Oncology Drug Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Roche
13.1.1 Roche Company Information
13.1.2 Roche Late-Stage Oncology Drug Product Portfolios and Specifications
13.1.3 Roche Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Roche Main Business Overview
13.1.5 Roche Latest Developments
13.2 Merck & Co
13.2.1 Merck & Co Company Information
13.2.2 Merck & Co Late-Stage Oncology Drug Product Portfolios and Specifications
13.2.3 Merck & Co Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Merck & Co Main Business Overview
13.2.5 Merck & Co Latest Developments
13.3 Bristol Myers
13.3.1 Bristol Myers Company Information
13.3.2 Bristol Myers Late-Stage Oncology Drug Product Portfolios and Specifications
13.3.3 Bristol Myers Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Bristol Myers Main Business Overview
13.3.5 Bristol Myers Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer Late-Stage Oncology Drug Product Portfolios and Specifications
13.4.3 Pfizer Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 Novartis
13.5.1 Novartis Company Information
13.5.2 Novartis Late-Stage Oncology Drug Product Portfolios and Specifications
13.5.3 Novartis Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Novartis Main Business Overview
13.5.5 Novartis Latest Developments
13.6 AstraZeneca
13.6.1 AstraZeneca Company Information
13.6.2 AstraZeneca Late-Stage Oncology Drug Product Portfolios and Specifications
13.6.3 AstraZeneca Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 AstraZeneca Main Business Overview
13.6.5 AstraZeneca Latest Developments
13.7 Johnson & Johnson
13.7.1 Johnson & Johnson Company Information
13.7.2 Johnson & Johnson Late-Stage Oncology Drug Product Portfolios and Specifications
13.7.3 Johnson & Johnson Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Johnson & Johnson Main Business Overview
13.7.5 Johnson & Johnson Latest Developments
13.8 Eli Lilly and Company
13.8.1 Eli Lilly and Company Company Information
13.8.2 Eli Lilly and Company Late-Stage Oncology Drug Product Portfolios and Specifications
13.8.3 Eli Lilly and Company Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Eli Lilly and Company Main Business Overview
13.8.5 Eli Lilly and Company Latest Developments
13.9 Sanofi
13.9.1 Sanofi Company Information
13.9.2 Sanofi Late-Stage Oncology Drug Product Portfolios and Specifications
13.9.3 Sanofi Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Sanofi Main Business Overview
13.9.5 Sanofi Latest Developments
13.10 AbbVie
13.10.1 AbbVie Company Information
13.10.2 AbbVie Late-Stage Oncology Drug Product Portfolios and Specifications
13.10.3 AbbVie Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 AbbVie Main Business Overview
13.10.5 AbbVie Latest Developments
13.11 GSK
13.11.1 GSK Company Information
13.11.2 GSK Late-Stage Oncology Drug Product Portfolios and Specifications
13.11.3 GSK Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 GSK Main Business Overview
13.11.5 GSK Latest Developments
13.12 Amgen
13.12.1 Amgen Company Information
13.12.2 Amgen Late-Stage Oncology Drug Product Portfolios and Specifications
13.12.3 Amgen Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Amgen Main Business Overview
13.12.5 Amgen Latest Developments
13.13 Genentech
13.13.1 Genentech Company Information
13.13.2 Genentech Late-Stage Oncology Drug Product Portfolios and Specifications
13.13.3 Genentech Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Genentech Main Business Overview
13.13.5 Genentech Latest Developments
13.14 Daiichi Sankyo Group
13.14.1 Daiichi Sankyo Group Company Information
13.14.2 Daiichi Sankyo Group Late-Stage Oncology Drug Product Portfolios and Specifications
13.14.3 Daiichi Sankyo Group Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Daiichi Sankyo Group Main Business Overview
13.14.5 Daiichi Sankyo Group Latest Developments
13.15 Aveo Oncology
13.15.1 Aveo Oncology Company Information
13.15.2 Aveo Oncology Late-Stage Oncology Drug Product Portfolios and Specifications
13.15.3 Aveo Oncology Late-Stage Oncology Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 Aveo Oncology Main Business Overview
13.15.5 Aveo Oncology Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Late-Stage Oncology Drug Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Late-Stage Oncology Drug Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Chemotherapy
Table 4. Major Players of Targeted Therapy
Table 5. Major Players of Immunotherapy
Table 6. Major Players of Hormonal Therapy
Table 7. Major Players of Others
Table 8. Global Late-Stage Oncology Drug Sales by Type (2019-2024) & (kg)
Table 9. Global Late-Stage Oncology Drug Sales Market Share by Type (2019-2024)
Table 10. Global Late-Stage Oncology Drug Revenue by Type (2019-2024) & ($ million)
Table 11. Global Late-Stage Oncology Drug Revenue Market Share by Type (2019-2024)
Table 12. Global Late-Stage Oncology Drug Sale Price by Type (2019-2024) & (US$/g)
Table 13. Global Late-Stage Oncology Drug Sale by Application (2019-2024) & (kg)
Table 14. Global Late-Stage Oncology Drug Sale Market Share by Application (2019-2024)
Table 15. Global Late-Stage Oncology Drug Revenue by Application (2019-2024) & ($ million)
Table 16. Global Late-Stage Oncology Drug Revenue Market Share by Application (2019-2024)
Table 17. Global Late-Stage Oncology Drug Sale Price by Application (2019-2024) & (US$/g)
Table 18. Global Late-Stage Oncology Drug Sales by Company (2019-2024) & (kg)
Table 19. Global Late-Stage Oncology Drug Sales Market Share by Company (2019-2024)
Table 20. Global Late-Stage Oncology Drug Revenue by Company (2019-2024) & ($ millions)
Table 21. Global Late-Stage Oncology Drug Revenue Market Share by Company (2019-2024)
Table 22. Global Late-Stage Oncology Drug Sale Price by Company (2019-2024) & (US$/g)
Table 23. Key Manufacturers Late-Stage Oncology Drug Producing Area Distribution and Sales Area
Table 24. Players Late-Stage Oncology Drug Products Offered
Table 25. Late-Stage Oncology Drug Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 26. New Products and Potential Entrants
Table 27. Market M&A Activity & Strategy
Table 28. Global Late-Stage Oncology Drug Sales by Geographic Region (2019-2024) & (kg)
Table 29. Global Late-Stage Oncology Drug Sales Market Share Geographic Region (2019-2024)
Table 30. Global Late-Stage Oncology Drug Revenue by Geographic Region (2019-2024) & ($ millions)
Table 31. Global Late-Stage Oncology Drug Revenue Market Share by Geographic Region (2019-2024)
Table 32. Global Late-Stage Oncology Drug Sales by Country/Region (2019-2024) & (kg)
Table 33. Global Late-Stage Oncology Drug Sales Market Share by Country/Region (2019-2024)
Table 34. Global Late-Stage Oncology Drug Revenue by Country/Region (2019-2024) & ($ millions)
Table 35. Global Late-Stage Oncology Drug Revenue Market Share by Country/Region (2019-2024)
Table 36. Americas Late-Stage Oncology Drug Sales by Country (2019-2024) & (kg)
Table 37. Americas Late-Stage Oncology Drug Sales Market Share by Country (2019-2024)
Table 38. Americas Late-Stage Oncology Drug Revenue by Country (2019-2024) & ($ millions)
Table 39. Americas Late-Stage Oncology Drug Sales by Type (2019-2024) & (kg)
Table 40. Americas Late-Stage Oncology Drug Sales by Application (2019-2024) & (kg)
Table 41. APAC Late-Stage Oncology Drug Sales by Region (2019-2024) & (kg)
Table 42. APAC Late-Stage Oncology Drug Sales Market Share by Region (2019-2024)
Table 43. APAC Late-Stage Oncology Drug Revenue by Region (2019-2024) & ($ millions)
Table 44. APAC Late-Stage Oncology Drug Sales by Type (2019-2024) & (kg)
Table 45. APAC Late-Stage Oncology Drug Sales by Application (2019-2024) & (kg)
Table 46. Europe Late-Stage Oncology Drug Sales by Country (2019-2024) & (kg)
Table 47. Europe Late-Stage Oncology Drug Revenue by Country (2019-2024) & ($ millions)
Table 48. Europe Late-Stage Oncology Drug Sales by Type (2019-2024) & (kg)
Table 49. Europe Late-Stage Oncology Drug Sales by Application (2019-2024) & (kg)
Table 50. Middle East & Africa Late-Stage Oncology Drug Sales by Country (2019-2024) & (kg)
Table 51. Middle East & Africa Late-Stage Oncology Drug Revenue Market Share by Country (2019-2024)
Table 52. Middle East & Africa Late-Stage Oncology Drug Sales by Type (2019-2024) & (kg)
Table 53. Middle East & Africa Late-Stage Oncology Drug Sales by Application (2019-2024) & (kg)
Table 54. Key Market Drivers & Growth Opportunities of Late-Stage Oncology Drug
Table 55. Key Market Challenges & Risks of Late-Stage Oncology Drug
Table 56. Key Industry Trends of Late-Stage Oncology Drug
Table 57. Late-Stage Oncology Drug Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59. Late-Stage Oncology Drug Distributors List
Table 60. Late-Stage Oncology Drug Customer List
Table 61. Global Late-Stage Oncology Drug Sales Forecast by Region (2025-2030) & (kg)
Table 62. Global Late-Stage Oncology Drug Revenue Forecast by Region (2025-2030) & ($ millions)
Table 63. Americas Late-Stage Oncology Drug Sales Forecast by Country (2025-2030) & (kg)
Table 64. Americas Late-Stage Oncology Drug Annual Revenue Forecast by Country (2025-2030) & ($ millions)
Table 65. APAC Late-Stage Oncology Drug Sales Forecast by Region (2025-2030) & (kg)
Table 66. APAC Late-Stage Oncology Drug Annual Revenue Forecast by Region (2025-2030) & ($ millions)
Table 67. Europe Late-Stage Oncology Drug Sales Forecast by Country (2025-2030) & (kg)
Table 68. Europe Late-Stage Oncology Drug Revenue Forecast by Country (2025-2030) & ($ millions)
Table 69. Middle East & Africa Late-Stage Oncology Drug Sales Forecast by Country (2025-2030) & (kg)
Table 70. Middle East & Africa Late-Stage Oncology Drug Revenue Forecast by Country (2025-2030) & ($ millions)
Table 71. Global Late-Stage Oncology Drug Sales Forecast by Type (2025-2030) & (kg)
Table 72. Global Late-Stage Oncology Drug Revenue Forecast by Type (2025-2030) & ($ millions)
Table 73. Global Late-Stage Oncology Drug Sales Forecast by Application (2025-2030) & (kg)
Table 74. Global Late-Stage Oncology Drug Revenue Forecast by Application (2025-2030) & ($ millions)
Table 75. Roche Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
Table 76. Roche Late-Stage Oncology Drug Product Portfolios and Specifications
Table 77. Roche Late-Stage Oncology Drug Sales (kg), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 78. Roche Main Business
Table 79. Roche Latest Developments
Table 80. Merck & Co Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
Table 81. Merck & Co Late-Stage Oncology Drug Product Portfolios and Specifications
Table 82. Merck & Co Late-Stage Oncology Drug Sales (kg), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 83. Merck & Co Main Business
Table 84. Merck & Co Latest Developments
Table 85. Bristol Myers Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
Table 86. Bristol Myers Late-Stage Oncology Drug Product Portfolios and Specifications
Table 87. Bristol Myers Late-Stage Oncology Drug Sales (kg), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 88. Bristol Myers Main Business
Table 89. Bristol Myers Latest Developments
Table 90. Pfizer Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
Table 91. Pfizer Late-Stage Oncology Drug Product Portfolios and Specifications
Table 92. Pfizer Late-Stage Oncology Drug Sales (kg), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 93. Pfizer Main Business
Table 94. Pfizer Latest Developments
Table 95. Novartis Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
Table 96. Novartis Late-Stage Oncology Drug Product Portfolios and Specifications
Table 97. Novartis Late-Stage Oncology Drug Sales (kg), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 98. Novartis Main Business
Table 99. Novartis Latest Developments
Table 100. AstraZeneca Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
Table 101. AstraZeneca Late-Stage Oncology Drug Product Portfolios and Specifications
Table 102. AstraZeneca Late-Stage Oncology Drug Sales (kg), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 103. AstraZeneca Main Business
Table 104. AstraZeneca Latest Developments
Table 105. Johnson & Johnson Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
Table 106. Johnson & Johnson Late-Stage Oncology Drug Product Portfolios and Specifications
Table 107. Johnson & Johnson Late-Stage Oncology Drug Sales (kg), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 108. Johnson & Johnson Main Business
Table 109. Johnson & Johnson Latest Developments
Table 110. Eli Lilly and Company Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
Table 111. Eli Lilly and Company Late-Stage Oncology Drug Product Portfolios and Specifications
Table 112. Eli Lilly and Company Late-Stage Oncology Drug Sales (kg), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 113. Eli Lilly and Company Main Business
Table 114. Eli Lilly and Company Latest Developments
Table 115. Sanofi Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
Table 116. Sanofi Late-Stage Oncology Drug Product Portfolios and Specifications
Table 117. Sanofi Late-Stage Oncology Drug Sales (kg), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 118. Sanofi Main Business
Table 119. Sanofi Latest Developments
Table 120. AbbVie Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
Table 121. AbbVie Late-Stage Oncology Drug Product Portfolios and Specifications
Table 122. AbbVie Late-Stage Oncology Drug Sales (kg), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 123. AbbVie Main Business
Table 124. AbbVie Latest Developments
Table 125. GSK Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
Table 126. GSK Late-Stage Oncology Drug Product Portfolios and Specifications
Table 127. GSK Late-Stage Oncology Drug Sales (kg), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 128. GSK Main Business
Table 129. GSK Latest Developments
Table 130. Amgen Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
Table 131. Amgen Late-Stage Oncology Drug Product Portfolios and Specifications
Table 132. Amgen Late-Stage Oncology Drug Sales (kg), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 133. Amgen Main Business
Table 134. Amgen Latest Developments
Table 135. Genentech Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
Table 136. Genentech Late-Stage Oncology Drug Product Portfolios and Specifications
Table 137. Genentech Late-Stage Oncology Drug Sales (kg), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 138. Genentech Main Business
Table 139. Genentech Latest Developments
Table 140. Daiichi Sankyo Group Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
Table 141. Daiichi Sankyo Group Late-Stage Oncology Drug Product Portfolios and Specifications
Table 142. Daiichi Sankyo Group Late-Stage Oncology Drug Sales (kg), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 143. Daiichi Sankyo Group Main Business
Table 144. Daiichi Sankyo Group Latest Developments
Table 145. Aveo Oncology Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
Table 146. Aveo Oncology Late-Stage Oncology Drug Product Portfolios and Specifications
Table 147. Aveo Oncology Late-Stage Oncology Drug Sales (kg), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 148. Aveo Oncology Main Business
Table 149. Aveo Oncology Latest Developments
Table 1. Late-Stage Oncology Drug Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Late-Stage Oncology Drug Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Chemotherapy
Table 4. Major Players of Targeted Therapy
Table 5. Major Players of Immunotherapy
Table 6. Major Players of Hormonal Therapy
Table 7. Major Players of Others
Table 8. Global Late-Stage Oncology Drug Sales by Type (2019-2024) & (kg)
Table 9. Global Late-Stage Oncology Drug Sales Market Share by Type (2019-2024)
Table 10. Global Late-Stage Oncology Drug Revenue by Type (2019-2024) & ($ million)
Table 11. Global Late-Stage Oncology Drug Revenue Market Share by Type (2019-2024)
Table 12. Global Late-Stage Oncology Drug Sale Price by Type (2019-2024) & (US$/g)
Table 13. Global Late-Stage Oncology Drug Sale by Application (2019-2024) & (kg)
Table 14. Global Late-Stage Oncology Drug Sale Market Share by Application (2019-2024)
Table 15. Global Late-Stage Oncology Drug Revenue by Application (2019-2024) & ($ million)
Table 16. Global Late-Stage Oncology Drug Revenue Market Share by Application (2019-2024)
Table 17. Global Late-Stage Oncology Drug Sale Price by Application (2019-2024) & (US$/g)
Table 18. Global Late-Stage Oncology Drug Sales by Company (2019-2024) & (kg)
Table 19. Global Late-Stage Oncology Drug Sales Market Share by Company (2019-2024)
Table 20. Global Late-Stage Oncology Drug Revenue by Company (2019-2024) & ($ millions)
Table 21. Global Late-Stage Oncology Drug Revenue Market Share by Company (2019-2024)
Table 22. Global Late-Stage Oncology Drug Sale Price by Company (2019-2024) & (US$/g)
Table 23. Key Manufacturers Late-Stage Oncology Drug Producing Area Distribution and Sales Area
Table 24. Players Late-Stage Oncology Drug Products Offered
Table 25. Late-Stage Oncology Drug Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 26. New Products and Potential Entrants
Table 27. Market M&A Activity & Strategy
Table 28. Global Late-Stage Oncology Drug Sales by Geographic Region (2019-2024) & (kg)
Table 29. Global Late-Stage Oncology Drug Sales Market Share Geographic Region (2019-2024)
Table 30. Global Late-Stage Oncology Drug Revenue by Geographic Region (2019-2024) & ($ millions)
Table 31. Global Late-Stage Oncology Drug Revenue Market Share by Geographic Region (2019-2024)
Table 32. Global Late-Stage Oncology Drug Sales by Country/Region (2019-2024) & (kg)
Table 33. Global Late-Stage Oncology Drug Sales Market Share by Country/Region (2019-2024)
Table 34. Global Late-Stage Oncology Drug Revenue by Country/Region (2019-2024) & ($ millions)
Table 35. Global Late-Stage Oncology Drug Revenue Market Share by Country/Region (2019-2024)
Table 36. Americas Late-Stage Oncology Drug Sales by Country (2019-2024) & (kg)
Table 37. Americas Late-Stage Oncology Drug Sales Market Share by Country (2019-2024)
Table 38. Americas Late-Stage Oncology Drug Revenue by Country (2019-2024) & ($ millions)
Table 39. Americas Late-Stage Oncology Drug Sales by Type (2019-2024) & (kg)
Table 40. Americas Late-Stage Oncology Drug Sales by Application (2019-2024) & (kg)
Table 41. APAC Late-Stage Oncology Drug Sales by Region (2019-2024) & (kg)
Table 42. APAC Late-Stage Oncology Drug Sales Market Share by Region (2019-2024)
Table 43. APAC Late-Stage Oncology Drug Revenue by Region (2019-2024) & ($ millions)
Table 44. APAC Late-Stage Oncology Drug Sales by Type (2019-2024) & (kg)
Table 45. APAC Late-Stage Oncology Drug Sales by Application (2019-2024) & (kg)
Table 46. Europe Late-Stage Oncology Drug Sales by Country (2019-2024) & (kg)
Table 47. Europe Late-Stage Oncology Drug Revenue by Country (2019-2024) & ($ millions)
Table 48. Europe Late-Stage Oncology Drug Sales by Type (2019-2024) & (kg)
Table 49. Europe Late-Stage Oncology Drug Sales by Application (2019-2024) & (kg)
Table 50. Middle East & Africa Late-Stage Oncology Drug Sales by Country (2019-2024) & (kg)
Table 51. Middle East & Africa Late-Stage Oncology Drug Revenue Market Share by Country (2019-2024)
Table 52. Middle East & Africa Late-Stage Oncology Drug Sales by Type (2019-2024) & (kg)
Table 53. Middle East & Africa Late-Stage Oncology Drug Sales by Application (2019-2024) & (kg)
Table 54. Key Market Drivers & Growth Opportunities of Late-Stage Oncology Drug
Table 55. Key Market Challenges & Risks of Late-Stage Oncology Drug
Table 56. Key Industry Trends of Late-Stage Oncology Drug
Table 57. Late-Stage Oncology Drug Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59. Late-Stage Oncology Drug Distributors List
Table 60. Late-Stage Oncology Drug Customer List
Table 61. Global Late-Stage Oncology Drug Sales Forecast by Region (2025-2030) & (kg)
Table 62. Global Late-Stage Oncology Drug Revenue Forecast by Region (2025-2030) & ($ millions)
Table 63. Americas Late-Stage Oncology Drug Sales Forecast by Country (2025-2030) & (kg)
Table 64. Americas Late-Stage Oncology Drug Annual Revenue Forecast by Country (2025-2030) & ($ millions)
Table 65. APAC Late-Stage Oncology Drug Sales Forecast by Region (2025-2030) & (kg)
Table 66. APAC Late-Stage Oncology Drug Annual Revenue Forecast by Region (2025-2030) & ($ millions)
Table 67. Europe Late-Stage Oncology Drug Sales Forecast by Country (2025-2030) & (kg)
Table 68. Europe Late-Stage Oncology Drug Revenue Forecast by Country (2025-2030) & ($ millions)
Table 69. Middle East & Africa Late-Stage Oncology Drug Sales Forecast by Country (2025-2030) & (kg)
Table 70. Middle East & Africa Late-Stage Oncology Drug Revenue Forecast by Country (2025-2030) & ($ millions)
Table 71. Global Late-Stage Oncology Drug Sales Forecast by Type (2025-2030) & (kg)
Table 72. Global Late-Stage Oncology Drug Revenue Forecast by Type (2025-2030) & ($ millions)
Table 73. Global Late-Stage Oncology Drug Sales Forecast by Application (2025-2030) & (kg)
Table 74. Global Late-Stage Oncology Drug Revenue Forecast by Application (2025-2030) & ($ millions)
Table 75. Roche Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
Table 76. Roche Late-Stage Oncology Drug Product Portfolios and Specifications
Table 77. Roche Late-Stage Oncology Drug Sales (kg), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 78. Roche Main Business
Table 79. Roche Latest Developments
Table 80. Merck & Co Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
Table 81. Merck & Co Late-Stage Oncology Drug Product Portfolios and Specifications
Table 82. Merck & Co Late-Stage Oncology Drug Sales (kg), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 83. Merck & Co Main Business
Table 84. Merck & Co Latest Developments
Table 85. Bristol Myers Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
Table 86. Bristol Myers Late-Stage Oncology Drug Product Portfolios and Specifications
Table 87. Bristol Myers Late-Stage Oncology Drug Sales (kg), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 88. Bristol Myers Main Business
Table 89. Bristol Myers Latest Developments
Table 90. Pfizer Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
Table 91. Pfizer Late-Stage Oncology Drug Product Portfolios and Specifications
Table 92. Pfizer Late-Stage Oncology Drug Sales (kg), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 93. Pfizer Main Business
Table 94. Pfizer Latest Developments
Table 95. Novartis Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
Table 96. Novartis Late-Stage Oncology Drug Product Portfolios and Specifications
Table 97. Novartis Late-Stage Oncology Drug Sales (kg), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 98. Novartis Main Business
Table 99. Novartis Latest Developments
Table 100. AstraZeneca Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
Table 101. AstraZeneca Late-Stage Oncology Drug Product Portfolios and Specifications
Table 102. AstraZeneca Late-Stage Oncology Drug Sales (kg), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 103. AstraZeneca Main Business
Table 104. AstraZeneca Latest Developments
Table 105. Johnson & Johnson Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
Table 106. Johnson & Johnson Late-Stage Oncology Drug Product Portfolios and Specifications
Table 107. Johnson & Johnson Late-Stage Oncology Drug Sales (kg), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 108. Johnson & Johnson Main Business
Table 109. Johnson & Johnson Latest Developments
Table 110. Eli Lilly and Company Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
Table 111. Eli Lilly and Company Late-Stage Oncology Drug Product Portfolios and Specifications
Table 112. Eli Lilly and Company Late-Stage Oncology Drug Sales (kg), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 113. Eli Lilly and Company Main Business
Table 114. Eli Lilly and Company Latest Developments
Table 115. Sanofi Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
Table 116. Sanofi Late-Stage Oncology Drug Product Portfolios and Specifications
Table 117. Sanofi Late-Stage Oncology Drug Sales (kg), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 118. Sanofi Main Business
Table 119. Sanofi Latest Developments
Table 120. AbbVie Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
Table 121. AbbVie Late-Stage Oncology Drug Product Portfolios and Specifications
Table 122. AbbVie Late-Stage Oncology Drug Sales (kg), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 123. AbbVie Main Business
Table 124. AbbVie Latest Developments
Table 125. GSK Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
Table 126. GSK Late-Stage Oncology Drug Product Portfolios and Specifications
Table 127. GSK Late-Stage Oncology Drug Sales (kg), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 128. GSK Main Business
Table 129. GSK Latest Developments
Table 130. Amgen Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
Table 131. Amgen Late-Stage Oncology Drug Product Portfolios and Specifications
Table 132. Amgen Late-Stage Oncology Drug Sales (kg), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 133. Amgen Main Business
Table 134. Amgen Latest Developments
Table 135. Genentech Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
Table 136. Genentech Late-Stage Oncology Drug Product Portfolios and Specifications
Table 137. Genentech Late-Stage Oncology Drug Sales (kg), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 138. Genentech Main Business
Table 139. Genentech Latest Developments
Table 140. Daiichi Sankyo Group Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
Table 141. Daiichi Sankyo Group Late-Stage Oncology Drug Product Portfolios and Specifications
Table 142. Daiichi Sankyo Group Late-Stage Oncology Drug Sales (kg), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 143. Daiichi Sankyo Group Main Business
Table 144. Daiichi Sankyo Group Latest Developments
Table 145. Aveo Oncology Basic Information, Late-Stage Oncology Drug Manufacturing Base, Sales Area and Its Competitors
Table 146. Aveo Oncology Late-Stage Oncology Drug Product Portfolios and Specifications
Table 147. Aveo Oncology Late-Stage Oncology Drug Sales (kg), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 148. Aveo Oncology Main Business
Table 149. Aveo Oncology Latest Developments
LIST OF FIGURES
Figure 1. Picture of Late-Stage Oncology Drug
Figure 2. Late-Stage Oncology Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Late-Stage Oncology Drug Sales Growth Rate 2019-2030 (kg)
Figure 7. Global Late-Stage Oncology Drug Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. Late-Stage Oncology Drug Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. Late-Stage Oncology Drug Sales Market Share by Country/Region (2023)
Figure 10. Late-Stage Oncology Drug Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture of Chemotherapy
Figure 12. Product Picture of Targeted Therapy
Figure 13. Product Picture of Immunotherapy
Figure 14. Product Picture of Hormonal Therapy
Figure 15. Product Picture of Others
Figure 16. Global Late-Stage Oncology Drug Sales Market Share by Type in 2023
Figure 17. Global Late-Stage Oncology Drug Revenue Market Share by Type (2019-2024)
Figure 18. Late-Stage Oncology Drug Consumed in Blood Cancer
Figure 19. Global Late-Stage Oncology Drug Market: Blood Cancer (2019-2024) & (kg)
Figure 20. Late-Stage Oncology Drug Consumed in Breast Cancer
Figure 21. Global Late-Stage Oncology Drug Market: Breast Cancer (2019-2024) & (kg)
Figure 22. Late-Stage Oncology Drug Consumed in Gastrointestinal Cancer
Figure 23. Global Late-Stage Oncology Drug Market: Gastrointestinal Cancer (2019-2024) & (kg)
Figure 24. Late-Stage Oncology Drug Consumed in Prostate Cancer
Figure 25. Global Late-Stage Oncology Drug Market: Prostate Cancer (2019-2024) & (kg)
Figure 26. Late-Stage Oncology Drug Consumed in Respiratory or Lung Cancer
Figure 27. Global Late-Stage Oncology Drug Market: Respiratory or Lung Cancer (2019-2024) & (kg)
Figure 28. Late-Stage Oncology Drug Consumed in Other
Figure 29. Global Late-Stage Oncology Drug Market: Other (2019-2024) & (kg)
Figure 30. Global Late-Stage Oncology Drug Sale Market Share by Application (2023)
Figure 31. Global Late-Stage Oncology Drug Revenue Market Share by Application in 2023
Figure 32. Late-Stage Oncology Drug Sales by Company in 2023 (kg)
Figure 33. Global Late-Stage Oncology Drug Sales Market Share by Company in 2023
Figure 34. Late-Stage Oncology Drug Revenue by Company in 2023 ($ millions)
Figure 35. Global Late-Stage Oncology Drug Revenue Market Share by Company in 2023
Figure 36. Global Late-Stage Oncology Drug Sales Market Share by Geographic Region (2019-2024)
Figure 37. Global Late-Stage Oncology Drug Revenue Market Share by Geographic Region in 2023
Figure 38. Americas Late-Stage Oncology Drug Sales 2019-2024 (kg)
Figure 39. Americas Late-Stage Oncology Drug Revenue 2019-2024 ($ millions)
Figure 40. APAC Late-Stage Oncology Drug Sales 2019-2024 (kg)
Figure 41. APAC Late-Stage Oncology Drug Revenue 2019-2024 ($ millions)
Figure 42. Europe Late-Stage Oncology Drug Sales 2019-2024 (kg)
Figure 43. Europe Late-Stage Oncology Drug Revenue 2019-2024 ($ millions)
Figure 44. Middle East & Africa Late-Stage Oncology Drug Sales 2019-2024 (kg)
Figure 45. Middle East & Africa Late-Stage Oncology Drug Revenue 2019-2024 ($ millions)
Figure 46. Americas Late-Stage Oncology Drug Sales Market Share by Country in 2023
Figure 47. Americas Late-Stage Oncology Drug Revenue Market Share by Country (2019-2024)
Figure 48. Americas Late-Stage Oncology Drug Sales Market Share by Type (2019-2024)
Figure 49. Americas Late-Stage Oncology Drug Sales Market Share by Application (2019-2024)
Figure 50. United States Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 51. Canada Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 52. Mexico Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 53. Brazil Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 54. APAC Late-Stage Oncology Drug Sales Market Share by Region in 2023
Figure 55. APAC Late-Stage Oncology Drug Revenue Market Share by Region (2019-2024)
Figure 56. APAC Late-Stage Oncology Drug Sales Market Share by Type (2019-2024)
Figure 57. APAC Late-Stage Oncology Drug Sales Market Share by Application (2019-2024)
Figure 58. China Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 59. Japan Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 60. South Korea Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 61. Southeast Asia Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 62. India Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 63. Australia Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 64. China Taiwan Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 65. Europe Late-Stage Oncology Drug Sales Market Share by Country in 2023
Figure 66. Europe Late-Stage Oncology Drug Revenue Market Share by Country (2019-2024)
Figure 67. Europe Late-Stage Oncology Drug Sales Market Share by Type (2019-2024)
Figure 68. Europe Late-Stage Oncology Drug Sales Market Share by Application (2019-2024)
Figure 69. Germany Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 70. France Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 71. UK Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 72. Italy Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 73. Russia Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 74. Middle East & Africa Late-Stage Oncology Drug Sales Market Share by Country (2019-2024)
Figure 75. Middle East & Africa Late-Stage Oncology Drug Sales Market Share by Type (2019-2024)
Figure 76. Middle East & Africa Late-Stage Oncology Drug Sales Market Share by Application (2019-2024)
Figure 77. Egypt Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 78. South Africa Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 79. Israel Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 80. Turkey Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 81. GCC Countries Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 82. Manufacturing Cost Structure Analysis of Late-Stage Oncology Drug in 2023
Figure 83. Manufacturing Process Analysis of Late-Stage Oncology Drug
Figure 84. Industry Chain Structure of Late-Stage Oncology Drug
Figure 85. Channels of Distribution
Figure 86. Global Late-Stage Oncology Drug Sales Market Forecast by Region (2025-2030)
Figure 87. Global Late-Stage Oncology Drug Revenue Market Share Forecast by Region (2025-2030)
Figure 88. Global Late-Stage Oncology Drug Sales Market Share Forecast by Type (2025-2030)
Figure 89. Global Late-Stage Oncology Drug Revenue Market Share Forecast by Type (2025-2030)
Figure 90. Global Late-Stage Oncology Drug Sales Market Share Forecast by Application (2025-2030)
Figure 91. Global Late-Stage Oncology Drug Revenue Market Share Forecast by Application (2025-2030)
Figure 1. Picture of Late-Stage Oncology Drug
Figure 2. Late-Stage Oncology Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Late-Stage Oncology Drug Sales Growth Rate 2019-2030 (kg)
Figure 7. Global Late-Stage Oncology Drug Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. Late-Stage Oncology Drug Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. Late-Stage Oncology Drug Sales Market Share by Country/Region (2023)
Figure 10. Late-Stage Oncology Drug Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture of Chemotherapy
Figure 12. Product Picture of Targeted Therapy
Figure 13. Product Picture of Immunotherapy
Figure 14. Product Picture of Hormonal Therapy
Figure 15. Product Picture of Others
Figure 16. Global Late-Stage Oncology Drug Sales Market Share by Type in 2023
Figure 17. Global Late-Stage Oncology Drug Revenue Market Share by Type (2019-2024)
Figure 18. Late-Stage Oncology Drug Consumed in Blood Cancer
Figure 19. Global Late-Stage Oncology Drug Market: Blood Cancer (2019-2024) & (kg)
Figure 20. Late-Stage Oncology Drug Consumed in Breast Cancer
Figure 21. Global Late-Stage Oncology Drug Market: Breast Cancer (2019-2024) & (kg)
Figure 22. Late-Stage Oncology Drug Consumed in Gastrointestinal Cancer
Figure 23. Global Late-Stage Oncology Drug Market: Gastrointestinal Cancer (2019-2024) & (kg)
Figure 24. Late-Stage Oncology Drug Consumed in Prostate Cancer
Figure 25. Global Late-Stage Oncology Drug Market: Prostate Cancer (2019-2024) & (kg)
Figure 26. Late-Stage Oncology Drug Consumed in Respiratory or Lung Cancer
Figure 27. Global Late-Stage Oncology Drug Market: Respiratory or Lung Cancer (2019-2024) & (kg)
Figure 28. Late-Stage Oncology Drug Consumed in Other
Figure 29. Global Late-Stage Oncology Drug Market: Other (2019-2024) & (kg)
Figure 30. Global Late-Stage Oncology Drug Sale Market Share by Application (2023)
Figure 31. Global Late-Stage Oncology Drug Revenue Market Share by Application in 2023
Figure 32. Late-Stage Oncology Drug Sales by Company in 2023 (kg)
Figure 33. Global Late-Stage Oncology Drug Sales Market Share by Company in 2023
Figure 34. Late-Stage Oncology Drug Revenue by Company in 2023 ($ millions)
Figure 35. Global Late-Stage Oncology Drug Revenue Market Share by Company in 2023
Figure 36. Global Late-Stage Oncology Drug Sales Market Share by Geographic Region (2019-2024)
Figure 37. Global Late-Stage Oncology Drug Revenue Market Share by Geographic Region in 2023
Figure 38. Americas Late-Stage Oncology Drug Sales 2019-2024 (kg)
Figure 39. Americas Late-Stage Oncology Drug Revenue 2019-2024 ($ millions)
Figure 40. APAC Late-Stage Oncology Drug Sales 2019-2024 (kg)
Figure 41. APAC Late-Stage Oncology Drug Revenue 2019-2024 ($ millions)
Figure 42. Europe Late-Stage Oncology Drug Sales 2019-2024 (kg)
Figure 43. Europe Late-Stage Oncology Drug Revenue 2019-2024 ($ millions)
Figure 44. Middle East & Africa Late-Stage Oncology Drug Sales 2019-2024 (kg)
Figure 45. Middle East & Africa Late-Stage Oncology Drug Revenue 2019-2024 ($ millions)
Figure 46. Americas Late-Stage Oncology Drug Sales Market Share by Country in 2023
Figure 47. Americas Late-Stage Oncology Drug Revenue Market Share by Country (2019-2024)
Figure 48. Americas Late-Stage Oncology Drug Sales Market Share by Type (2019-2024)
Figure 49. Americas Late-Stage Oncology Drug Sales Market Share by Application (2019-2024)
Figure 50. United States Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 51. Canada Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 52. Mexico Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 53. Brazil Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 54. APAC Late-Stage Oncology Drug Sales Market Share by Region in 2023
Figure 55. APAC Late-Stage Oncology Drug Revenue Market Share by Region (2019-2024)
Figure 56. APAC Late-Stage Oncology Drug Sales Market Share by Type (2019-2024)
Figure 57. APAC Late-Stage Oncology Drug Sales Market Share by Application (2019-2024)
Figure 58. China Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 59. Japan Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 60. South Korea Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 61. Southeast Asia Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 62. India Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 63. Australia Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 64. China Taiwan Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 65. Europe Late-Stage Oncology Drug Sales Market Share by Country in 2023
Figure 66. Europe Late-Stage Oncology Drug Revenue Market Share by Country (2019-2024)
Figure 67. Europe Late-Stage Oncology Drug Sales Market Share by Type (2019-2024)
Figure 68. Europe Late-Stage Oncology Drug Sales Market Share by Application (2019-2024)
Figure 69. Germany Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 70. France Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 71. UK Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 72. Italy Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 73. Russia Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 74. Middle East & Africa Late-Stage Oncology Drug Sales Market Share by Country (2019-2024)
Figure 75. Middle East & Africa Late-Stage Oncology Drug Sales Market Share by Type (2019-2024)
Figure 76. Middle East & Africa Late-Stage Oncology Drug Sales Market Share by Application (2019-2024)
Figure 77. Egypt Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 78. South Africa Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 79. Israel Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 80. Turkey Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 81. GCC Countries Late-Stage Oncology Drug Revenue Growth 2019-2024 ($ millions)
Figure 82. Manufacturing Cost Structure Analysis of Late-Stage Oncology Drug in 2023
Figure 83. Manufacturing Process Analysis of Late-Stage Oncology Drug
Figure 84. Industry Chain Structure of Late-Stage Oncology Drug
Figure 85. Channels of Distribution
Figure 86. Global Late-Stage Oncology Drug Sales Market Forecast by Region (2025-2030)
Figure 87. Global Late-Stage Oncology Drug Revenue Market Share Forecast by Region (2025-2030)
Figure 88. Global Late-Stage Oncology Drug Sales Market Share Forecast by Type (2025-2030)
Figure 89. Global Late-Stage Oncology Drug Revenue Market Share Forecast by Type (2025-2030)
Figure 90. Global Late-Stage Oncology Drug Sales Market Share Forecast by Application (2025-2030)
Figure 91. Global Late-Stage Oncology Drug Revenue Market Share Forecast by Application (2025-2030)
